• Users Online: 27969
  • Home
  • Print this page
  • Email this page
This article has been cited by
1Effect of Intravitreal Injections on Retinal Imaging Metrics in Glaucomatous and Non-Glaucomatous Eyes
Ronaldo Nuesi,Swarup S. Swaminathan
Current Ophthalmology Reports.2020;8(3)111
[DOI]
2Changing trends in the use of anti-vascular endothelial growth factor (anti-VEGF) biosimilars: Insights from the Vitreoretinal Society of India Biosimilars of Anti-VEGF Survey
JayU Sheth,MichaelW Stewart,Manoj Khatri,ShashankR Gupta,Shobhit Chawla,Anand Rajendran,Raja Narayanan
Indian Journal of Ophthalmology.2021;69(2)352
[DOI]
3Real-World Outcomes of Anti-VEGF Therapy in Diabetic Macular Oedema: Barriers to Treatment Success and Implications for Low/Lower-Middle-Income Countries
Olapeju A. Sam-Oyerinde,Praveen J. Patel
Ophthalmology and Therapy.2023;12(2)809
[DOI]
4AAVrh-10 transduces outer retinal cells in rodents and rabbits following intravitreal administration
Yong Zeng,Haohua Qian,Zhijian Wu,Dario Marangoni,Paul A. Sieving,Ronald A. Bush
Gene Therapy.2019;26(9)386
[DOI]
5Intravitreal OZURDEX vs. Intravitreal Bevacizumab for Diabetic Macular Edema: A Comprehensive Review
Raina Jain,Sachin Daigavane
Cureus.2024;26(9)386
[DOI]
6Bevacizumab
Raina Jain,Sachin Daigavane
Reactions Weekly.2017;1680(1)69
[DOI]
7Commentary: All India Ophthalmological Society members' survey: Practice pattern of intravitreal anti-vascular endothelial growth factor injection
Giridhar Anantharaman
Indian Journal of Ophthalmology.2020;68(6)1099
[DOI]
8Visual outcomes, safety profile and morphometric response of optical coherence tomography biomarkers to ranibizumab biosimilar treatment in neovascular age-related macular degeneration: Real-world evidence
AdityaS Kelkar,Jai Kelkar,Mounika Bolisetty,ShreekantB Kelkar
Indian Journal of Ophthalmology.2021;69(6)1469
[DOI]
9The Impact of COVID-19 on Intravitreal Injection Compliance
Lauren M. Wasser,Yishay Weill,Koby Brosh,Itay Magal,Michael Potter,Israel Strassman,Evgeny Gelman,Meni Koslowsky,David Zadok,Joel Hanhart
SN Comprehensive Clinical Medicine.2020;2(12)2546
[DOI]
10Real-World Safety Outcomes of Intravitreal Ranibizumab Biosimilar (Razumab) Therapy for Chorioretinal Diseases
Debdulal Chakraborty,Michael W. Stewart,Jay U. Sheth,Tushar K. Sinha,Subhendu Boral,Arnab Das,Soumen Mondal,Angshuman Mukherjee
Ophthalmology and Therapy.2021;10(2)337
[DOI]
11Safety and efficacy of ranibizumab biosimilar (Razumab®) as a cost-effective alternative to the innovator molecule for macular disorders in real-world
Sonal Paliwal,Riddhima Deshpande,Prerna Upadhyay
Indian Journal of Clinical and Experimental Ophthalmology.2023;9(3)329
[DOI]
12Efficacy of an Indian Bevacizumab BIOSimilar (BEVATAS) for Type 1 and Aggressive Posterior Retinopathy of Prematurity (BIOS-ROP Study)
Somnath Chakraborty,Jay Sheth
Clinical Ophthalmology.2024;Volume 18(3)61
[DOI]
13Real-World Evidence in the Management of Diabetic Macular Edema with Intravitreal Anti-VEGFs in Asia: A Systematic Literature Review
Yew Sen Yuen,Gavin Siew Wei Tan,Nicola Yi'An Gan,Issac Horng Khit Too,Raj Kumar Mothe,Pradeep Basa,Javed Shaikh
Clinical Ophthalmology.2022;Volume 16(3)3503
[DOI]

Subscribe this journal
Submit articles
Most popular articles
Joiu us as a reviewer
Email alerts
Recommend this journal